Navigation Links
IDEV Technologies Receives FDA Clearance for Its SUPERA VERITAS® 6 French Stent Delivery System
Date:11/10/2011

WEBSTER, Texas, Nov. 10, 2011 /PRNewswire/ -- IDEV Technologies, Incorporated (IDEV), today announced the FDA has granted 510(k) clearance for the company's 6 French (6Fr) SUPERA VERITAS Transhepatic Biliary Stent System.  The new lower profile system, approved for sale outside the U.S. earlier this year, is the latest enhancement to the delivery catheter utilized with the unique SUPERA stent, currently cleared in the U.S. for palliative treatment of biliary strictures produced by malignant neoplasms.

In addition to having a lower entry profile, the new 6Fr system is available in two catheter lengths, 80 cm and 120 cm, and offers even better efficiency and trackability.

"Feedback from our European customers confirms the new 6Fr system allows for improved ease of use, trackability and control of stent deployment," commented Christopher M. Owens, President and CEO of IDEV.  "As the global market continues to move toward smaller delivery sizes, we believe these regulatory clearances will provide an opportunity to accelerate market expansion and adoption of our technology.  We are pleased to now have this product available to our U.S. customers and patients."

Full commercial launch of the 6Fr SUPERA VERITAS Transhepatic Biliary Stent System is anticipated in January 2012.

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.

The SUPERA stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe, Canada, Australia and Hong Kong for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).

For more information please visit www.idevmd.com. Contact:

Donna LucchesiVice President Global MarketingIDEV Technologies, Incorporated(281) 525-2000
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Upgraded ACCF/ AHA/ SCAI Guidelines Reinforce Benefits of Volcanos Precision Guided Therapy Technologies
2. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
4. BioMarCare Technologies Ltd. Granted Access to Archived Samples in the Hadassah Medical Center
5. Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
6. Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair
7. Micell Technologies Announces Presentation of Clinical Data at TCT 2011
8. China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011
9. AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
10. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
11. Connectyx Technologies to Host Teleconference on Third Quarter Financial Results on Tuesday November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 30, 2017  Lannett Company, Inc. (NYSE: ... a $25 million payment against its existing revolving credit ... with the $75 million payment we made earlier this ... in annualized cash interest expense, at current rates" said ... "Our business is solid and we continue to generate ...
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose Inhalers, Dry ... Respiratory Inhalers - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover how ...
(Date:3/30/2017)... , March 30, 2017  Purcell Julie & Lefkowitz LLP, ... is investigating a potential breach of fiduciary duty claim involving ... SGYP ). If you are a ... information regarding this investigation, free of charge, please visit us ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag ... network of more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, ... mowers and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, the ... New York City-based sports and entertainment marketing firm Leverage Agency as its exclusive ... the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming rights, ...
(Date:3/29/2017)... ... 30, 2017 , ... Grass pollen is the main cause of hay fever in the United ... for grass pollen runs from May to July each year; with the worst time for ... HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they ...
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in ... who have participated in the program every summer. The 2017 Serve, Learn, & ... enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Sports Brand EXOUS ... brace, which retails normally at $29.97; for the remaining days of March, the price ... been reduced to a special price of just $10 (regular retail price $19.97). , ...
Breaking Medicine News(10 mins):